Analyst firms · Barclays · BIIB

Barclays BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

Barclays rates Biogen Inc. (BIIB) Equal Weight with a $185 price target, as of its latest action on Feb 20, 2026. It has published 4 rating actions on BIIB since October 2021, including 0 upgrades and 0 downgrades. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. Barclays's $185 is 20% below that.

Current rating
Equal Weight
Price target
$185
Median target, all firms
$231.50
Actions on BIIB
4

Barclays price target on BIIB

$290$238$18520222023202420252026
Barclays price target on BIIB, each point a stated target, October 2021 to February 2026.

Every Barclays rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about Barclays and BIIB

What is Barclays's price target for BIIB?
Barclays's latest stated price target for Biogen Inc. (BIIB) is $185, from its action on Feb 20, 2026.
What is Barclays's rating on BIIB?
Barclays rates BIIB Equal Weight, a neutral rating, as of Feb 20, 2026.
When did Barclays last change its view on BIIB?
On Feb 20, 2026, Barclays starts coverage at Equal Weight, price target $185.
How does Barclays's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50. Barclays's $185 is 20% below that.

More BIIB rating histories

All Barclays ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.